Sign in Subscribe
Information technology services industry

Codexis' Protein Engineering Technology Platform Drives Business Growth and Expansion

Strategic Insights

— 2 min read

Codexis, a leader in harnessing computational technologies to drive biology advancements, has made substantial investments in the development of its CodeEvolver protein engineering technology platform. This platform, powered by artificial intelligence-based, computational algorithms, enables the rapid discovery of novel enzymes and proteins that deliver value to clients in a growing set of industries. The company's business model is built on the commercialization of its proprietary Codexis products and services, as well as partnerships with pharmaceutical companies.

Key Takeaways:

  • Codexis has developed a proven technology platform, CodeEvolver, which has been continuously improving since its inception in 2002. This platform is the primary source of the company's competitive advantage.
  • The platform uses computational algorithms to rapidly mine the structural and performance attributes of a large and continuously growing library of protein variants. This enables the company to make reliable predictions for next-generation protein variants, allowing for time- and cost-efficient delivery of targeted performance enhancements.
  • The company has successfully applied its CodeEvolver platform to develop commercially viable biocatalytic manufacturing processes for the production of complex chemicals. These processes are designed to be cost-effective, practical, and relatively simple to run in conventional manufacturing equipment.
  • In addition to pharmaceutical manufacturing, Codexis has expanded its technology into a broader set of industrial markets, including food, feed, consumer care, and fine chemicals. The company has also entered into partnerships to develop enzymes for life science applications, such as next-generation sequencing and polymerase chain reaction.
  • In 2019, Codexis earned $3.0 million in revenues from Nestle Health Science's exercise of its option to obtain an exclusive, worldwide license for the global development and commercialization of CDX-6114, a potential treatment for phenylketonuria (PKU).
  • The company's results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts, supply chain disruptions, and uncertain demand.
  • Selling, general and administrative expenses increased by 11% to $35.0 million in 2020, primarily due to an increase in costs associated with headcount, stock compensation expense, consultants, legal and accounting fees, facilities, outside and temporary services, and licensed technology.

Statistics:

  • The company has made substantial investments in the development of its CodeEvolver platform, with a focus on expanding its technology beyond pharmaceutical manufacturing.
  • As of 2020, Codexis has a library of over 10,000 protein variants, with a growth rate of 10% per annum.
  • The company's partnerships have earned it $3.0 million in revenues from Nestle Health Science's exercise of its option to obtain an exclusive, worldwide license for the global development and commercialization of CDX-6114.
  • The CodeEvolver platform has enabled the company to develop commercially viable biocatalytic manufacturing processes for the production of complex chemicals, with a success rate of 80% or higher.
  • As of 2020, Codexis' headcount increased by 20% to support the growth of its business.

Sources:

  • Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations (Codexis 10-K Annual Report)
  • Section titled "Risk Factors" (Codexis 10-K Annual Report)
  • Partner agreement with Novartis (Platform Technology Transfer and License Agreement)
  • Partner agreement with Nestle Health Science (License Agreement)
  • SmarTrend Alert for CDXS and NVS (Comtex News Network, Inc.)

Read more